Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan

Abstract Background International guidelines recommend ivosidenib followed by modified FOLFOX (mFOLFOX) for advanced intrahepatic cholangiocarcinoma (ICC) with isocitrate dehydrogenase 1 (IDH1) mutations. Taiwan National Health Insurance covers only fluorouracil/leucovorin (5-FU/LV) chemotherapy for...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kuei-An Chen, Wei-Ming Huang, Eric Yi-Ting Chen, Pei-Kuan Ho, Chen-Han Chueh, Yu-Wen Wen, Ming-Huang Chen, Nai-Jung Chiang, Yi-Wen Tsai
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-05-01
coleção:	BMC Cancer
Assuntos:	Ivosidenib Cost-effectiveness Advanced intrahepatic cholangiocarcinoma IDH1 mutations
Acesso em linha:	https://doi.org/10.1186/s12885-024-12362-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!